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Abstract 
The prevalence and the clinical relevance of dermatophytoses in HIV-infected patients 
are poorly documented, particularly for those caused by tinea incognito. Here, we report 
a case of widespread facial tinea incognito occurring in an Italian patient with advanced 
HIV infection, showing both skin and brain lesions. Second-line treatment with liposomal 
amphotericin B and cotrimoxazole, administered after a microbiological characterization 
of the skin scrapings, led to complete clearance of all lesions. 
 
Introduction 
Dermatophytoses are localized fungal infections of the skin, interdigital space, groin 
and hair; they are very common in the general population and do not usually cause 
serious clinical diseases [1]. The prevalence of dermatophytoses in HIV-infected patients 
is poorly documented and may be underestimated in those living in developed countries, 
due to the early start of antiretroviral therapy in recent years and to the frequent use of 
azoles, both for prophylaxis and therapy of other fungal diseases [2]. 
Tinea incognito is a peculiar dermatophytosis with altered, polymorphic 
manifestations, lacking most of the typical morphological features that characterize tinea 
corporis, including round or oval presentation, sharp edges, vesicles, and scaling. It is 
commonly due to topical immunosuppressive agents, like steroids. Tinea incognito is 
frequently misdiagnosed as psoriasis, contact dermatitis and other types of eczema,  
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rosacea, and lupus erythematosus. Cultures from tinea incognito usually yield the same 
dermatophytes isolated from typical dermatophytoses, the most frequently reported in 
Europe being Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, 
Epidermophyton floccosum, and Microsporum gypseum [3, 4]. 
In the present study, we report a case of diffuse and persistent tinea incognito caused 
by M. gypseum in a patient with advanced HIV disease experiencing clinical progression 
and an isolated brain lesion. 
Case Report 
A 37-year-old male drug addict was diagnosed with HIV and HCV infection in 1996. Antiretroviral 
therapy was started in 1997, when his CD4 T-cell counts were 236/mm
3 and his viral load was 23,104 
copies/ml. His adherence to antiretrovirals was suboptimal until 2005. He carried on a dual therapy with 
zidovudine and didanosine at standard doses until 1998, when he was switched to his first highly active 
antiretroviral therapy (HAART) regimen including stavudine, lamivudine, nevirapine and nelfinavir. 
He remained on this HAART regimen with poor adherence until clinical progression late in 2005. His 
HIV viral load never exceeded 30,000 copies/ml; CD4 T-cell counts ranged from 30 to 120/mm
3, with 
liver function tests always in the normal range. During this period, he worked as a floor-cleaning 
assistant. 
In absence of any signs of clinical progression, the patient came to our institution in May 2005, due 
to dermatological lesions confined to his face and neck. Lesions consisted of annular erythematous scaly 
plaques with inflammatory advancing borders located on the upper lip, nose and side of the neck (fig. 
1). Dermatophytosis was clinically diagnosed, and oral itraconazole, 200 mg b.i.d., was prescribed until 
September 2005, when his condition had completely cleared. Thus, we decided to stop the antifungal 
therapy. The patient missed a few programmed checks. In January 2006, he came again to our 
institution because of a relapse of his facial disease. Lesions consisted of ill-defined, confluent, poorly 
inflammatory erythematous scaly patches, diffusely involving the face and neck (fig. 2a, b). Itraconazole 
at the same dosage (400 mg daily) was started again, without benefit. A second dermatologist prescribed 
biotin and topical steroids after a clinical diagnosis of seborrheic dermatitis. After a few days, the patient 
was hospitalized on emergency due a generalized convulsive episode. MRI contrast imaging 
documented an isolated, superficial brain lesion, 1 cm in size, involving the central circumvolution of 
his right parietal lobe, causing remarkable perilesional edema. A few days later, a contrast CT scan of the 
brain revealed a hypodense cortical and subcortical lesion at the same site as detected by MRI, with 
normal appearance of the remaining brain parenchyma. Sampling of CSF documented a mild increase 
in CSF proteins, whereas PCR and cultural assays for herpes viruses, Toxoplasma gondii and 
Mycobacterium tuberculosis were negative. His liver function tests worsened, CD4 T-cell counts being 
20/mm
3. A skin scraping was performed, showing the presence of numerous hyaline septate hyphae. 
Cultural assays, both on Sabouraud dextrose agar and cycloheximide-added Sabouraud dextrose agar, 
yielded fungal isolates after a few days of incubation. Macro- and micromorphologic examinations 
identified the geophilic species M. gypseum. Intravenous cotrimoxazole, 70 mg/kg daily, as well as 
liposomal amphotericin B, 3 mg/kg daily, were started suspecting neurotoxoplasmosis and/or cerebral 
mycosis. A few days later, after evaluation of a GRT for HIV resistance mutations, a salvage HAART 
regimen was initiated, including enfuvirtide, tipranavir/r, zidovudine, tenofovir and lamivudine. At the 
ninth week of therapy, when 3 mg/kg liposomal amphotericin B was still administered 3 times weekly 
for maintenance, lower limb edemas ensued. Renal function tests revealed serum creatinine at 6.4 
mg/dl, total serum nitrogen at 88 mg/dl, and severe proteinuria (1,600 mg/l). CD4 T-cell counts were 
122/mm
3, HIV viremia was undetectable (<50 copies/ml). At this time, the cutaneous lesions had 
cleared, and his cerebral lesion was still detectable on a control CT scan, although much reduced in size. 
Tenofovir and liposomal amphotericin B were interrupted, whereas the remaining HAART regimen 
was continued. Itraconazole was restarted at a dose of 200 mg twice daily. Enfuvirtide was discontinued 
after 6 additional months. Renal function normalized 40 days after modification of the antiretroviral 
regimen, and a renal sequential scintigram showed a normal perfusion pattern at the same time; full 
reversion of proteinuria and peripheral edemas ensued. As of January 2011, approximately 4 years after 
the acute renal toxicity episode, CD4 T-cell counts were 389/mm
3 and HIV viremia was persistently 
suppressed.   
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We report a case of tinea incognito involving the face and neck in a patient working as 
a floor-cleaning assistant, with long-lasting HIV infection and severe HIV-related 
immune depression. First-line systemic treatment with itraconazole was temporarily 
successful. At relapse of the cutaneous lesions, however, an unsuccessful second-line 
regimen with topical steroids was administered, based on the eczematous-like appearance 
of the patient’s diffuse facial lesions, in absence of a microbiological characterization. 
Finally, M. gypseum was isolated from culture of progressed lesions. To our knowledge, 
this geophilic dermatophyte has been reported in only a few cases of HIV patients so far, 
and always in resource-poor settings [5–8]. Our case, therefore, is the first case of diffuse 
tinea incognito due to M. gypseum reported in Western countries in a patient with 
prolonged professional exposure to soil and dust and severe immune suppression [9]. 
In our case, tinea incognito, commonly originating from topical corticosteroid 
treatment, was likely related to the severe and long-lasting depletion and consequent loss 
of function of CD4 T-lymphocytes. It thus adds to the evidence that dermatological 
diagnosis should never be based upon the sole appearance of lesions in HIV patients with 
advanced disease, the contribution of laboratory examination being essential. 
Misdiagnosis often leads to an inappropriate use of drugs as topical or systemic 
corticosteroids, possibly causing further spread of tinea incognito [4, 10]. 
In our patient, skin involvement due to M. gypseum was diagnosed together with a 
lesion of the right parietal cortex brain causing seizures. Initially, we suspected a CNS 
infection caused by T. gondii. Brain CT scan findings, however, were atypical for 
neurotoxoplasmosis, showing no involvement of the basal ganglia and normal ventricular 
appearance. In addition, the search for T. gondii DNA in CSF by PCR was negative. A 
broad-spectrum antimicrobial regimen based on cotrimoxazole and liposomal 
amphotericin B, together with a rescue HAART regimen, led to a reversal of the patient’s 
severe immune suppression and to the clearance of both skin and brain lesions. 
Consequently, we cannot exclude that the observed isolated brain lesion might have been 
caused by M. gypseum itself, being responsive to systemic liposomal amphotericin B and 
immune rescue.  
Our patient had never shown adequate adherence to antiretroviral treatment since he 
was diagnosed with HIV infection. Interestingly, the occurrence of a state of severe 
clinical impairment, characterized by combined skin and brain lesions, led to a 
remarkable and long-lasting increase in adherence to therapy, even during 
coadministration of a complex antibiotic and antifungal regimen, as well as when severe 
renal toxicity might have easily discouraged full adherence [11, 12]. 
In conclusion, our case report may represent the first evidence of tinea incognito in a 
patient with advanced HIV infection and a concomitant reversible CNS lesion, possibly 
related to the relapse of his cutaneous lesion. Microbiological characterization of skin 
lesions in advanced HIV patients may play a clinically relevant adjuvant role.  
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Fig. 1. Picture of the face and neck of the patient taken at the time of the first diagnosis of 
dermatophytosis. Lesions appeared as two ring-shaped, erythematous scaly plaques with inflammatory 
advancing borders located on the upper lip, nose and side of the neck. 
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Fig. 2. Lesions on the neck and face of the patient at the time of relapse, approximately six months 
after the first diagnosis. They consist of ill-defined, confluent, scantly inflammatory erythematous scaly 
patches, diffusely involving the face and neck. 
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